Intensified P2Y12 inhibition for high-on treatment platelet reactivity.

Journal of Thrombosis and Thrombolysis
Fakilahyel S MshelbwalaRolf P Kreutz

Abstract

High on treatment platelet reactivity (HPR) during treatment with clopidogrel has been consistently found to be strong risk factor for recurrent ischemic events after percutaneous coronary intervention (PCI). Insufficient P2Y12 receptor inhibition contributes to HPR measured by the VerifyNow (VN) assay. Prasugrel and ticagrelor are more potent P2Y12 inhibitors than clopidogrel and commonly substituted for clopidogrel when HPR is documented, however benefit of VN guided intensified antiplatelet therapy is uncertain. We identified patients who had undergone platelet reactivity testing after PCI with VN after pretreatment with clopidogrel (n = 252) in a single center observational analysis. Patients who had HPR defined as PRU > 208 were switched to alternate P2Y12 inhibitors. Primary clinical endpoint was 1-year post PCI combined cardiovascular death, myocardial infarction (MI), and stent thrombosis. One hundred and eight (43%) subjects had HPR and were switched to prasugrel (n = 60) and ticagrelor (n = 48). Risk of recurrent 1-year primary endpoint remained higher for HPR patients switched to either ticagrelor or prasugrel as compared to subjects who had low on treatment platelet reactivity (n = 144) (LPR) on clopidogrel [Hazard ...Continue Reading

References

Jul 1, 2004·Expert Review of Cardiovascular Therapy·Paul A GurbelUdaya Tantry
Nov 16, 2005·Journal of the American College of Cardiology·Paul A GurbelUdaya S Tantry
May 2, 2007·Circulation·Donald E CutlipUNKNOWN Academic Research Consortium
May 20, 2009·Circulation·Matthew J Price
Feb 25, 2010·JAMA : the Journal of the American Medical Association·Nicoline J BreetJurriën M ten Berg
Sep 11, 2010·Journal of the American College of Cardiology·Laurent BonelloUNKNOWN Working Group on High On-Treatment Platelet Reactivity
Nov 18, 2011·JAMA : the Journal of the American Medical Association·Jessica L MegaMarc S Sabatine
Mar 20, 2012·Clinical Pharmacology : Advances and Applications·Rolf P KreutzYan Jin
Nov 6, 2012·The New England Journal of Medicine·Jean-Philippe ColletUNKNOWN ARCTIC Investigators
Aug 29, 2017·The New England Journal of Medicine·John W EikelboomUNKNOWN COMPASS Investigators
Dec 28, 2017·Clinical Pharmacology and Therapeutics·Philip E EmpeyUNKNOWN IGNITE Network
May 26, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Miao WangUNKNOWN Early Career Committee
Aug 30, 2018·Journal of the American College of Cardiology·Kristian ThygesenUNKNOWN Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American He
Mar 19, 2019·TH Open : Companion Journal to Thrombosis and Haemostasis·Rolf P KreutzJeffrey A Breall
Apr 19, 2019·Circulation. Cardiovascular Interventions·Naveen L PereiraMichael E Farkouh
Sep 3, 2019·The New England Journal of Medicine·Stefanie SchüpkeUNKNOWN ISAR-REACT 5 Trial Investigators
Sep 4, 2019·The New England Journal of Medicine·Daniel M F ClaassensJurriën M Ten Berg

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.